High Serum Homocysteine Levels in Young Male Schizophrenic and Schizoaffective Patients With Tardive Parkinsonism and/or Tardive Dyskinesia
J Clin Psychiatry 2005;66(12):1558-1563
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: The pathogenesis of
neuroleptic-induced tardive movement disorders (TMD),
including tardive parkinsonism and tardive dyskinesia (TD),
has not yet been established. An elevated serum level
of total homocysteine has been implicated as a risk
factor for various neuropathologic states and some
movement disorders. The aim of our study was to
determine whether there is an association between serum
total homocysteine level and the presence of TMD
among schizophrenic and schizoaffective patients.
Method: This study was conducted in Be'er
Sheva Mental Health Center from August 2002 to May
2004. Fifty-eight patients with schizophrenia or
schizoaffective disorder (DSM-IV) and TMD for at least 1
year (38 men, 20 women; age range, 28-73 years)
were compared to a control group of 188 patients
with DSM-IV-diagnosed schizophrenia or
schizoaffective disorder without TMD (123 men, 65 women;
age range, 19-66 years) regarding serum total homocysteine levels.
Results: Men with TMD (demonstrating
tardive parkinsonism and/or TD) had significantly
higher mean serum total homocysteine levels compared
to sex- and age group-matched controls. The
difference between groups was almost entirely attributable to
the homocysteine levels of young male patients
(age group, 19-40 years old) with TMD.
Conclusion: High serum total homocysteine
level may constitute a risk factor for certain variants
of TMD, especially in young schizophrenic or
schizoaffective male patients. Further prospective studies
are needed to clarify these findings.